Latest Industry Insights

Technology Networks recently had the pleasure of speaking with Novavax to discuss their current progress in COVID-19 vaccine development.

The Feinstein Institutes is collaborating with Gilead Sciences and Regeneron Pharmaceuticals in an effort to identify effective therapeutic treatments against COVID-19. Technology Networks recently had the pleasure of speaking with Kevin Tracey, CEO and President of the Feinstein Institutes for Medical Research to find out more.

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.

Early stage biotech company Aqualung Therapeutics is currently developing a therapeutic monoclonal antibody – ALT-100 – for the treatment of unchecked inflammation. COVID-19 can cause severe pneumonia and respiratory failure. There is therefore a potential option to treat patients diagnosed with COVID-19 with ALT-100. Technology Networks recently spoke with Joe Garcia, MD, Founder and Chief Executive Officer of Aqualung Therapeutics to learn more.

CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.

With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.

The study of brain tumors using real-time imaging of the brain in live disease models is critical for elucidating disease mechanisms and developing novel treatment strategies. Such research requires full characterization of healthy and disease phenotypes using a multi-omics analysis, as described in this blog.

Technology Networks recently spoke with Stephen Williams, CMO at biotechnology company SomaLogic, to learn more about research progress in the proteomics space and the technology that has enabled it.

Many biotherapeutic drugs such as recombinant antibodies are manufactured utilizing host cells, a common example being Chinese hamster ovary (CHO) cells. A key factor for consideration in this process is the growth and viability of these cells – ultimately this influences the quality and quantity of the biotherapeutic product. Technology Networks spoke with Nicole Wellens, Global Product Manager for BioTherapeutics Media, Lonza to learn more about the new feed and how it has been developed.

In this interview, Gaia Fancellu, of Iceni Diagnostics, talks about her work in more detail, discusses the challenges of studying GSDs, and highlights the advantages of using a “Systems Medicine” approach to do so.